Conformationnally restricted naphthalene derivatives type isocombretastatin A-4 and isoerianin analogues: Synthesis, cytotoxicity and antitubulin activity-Reference-Cited by-同舟云学术

Conformationnally restricted naphthalene derivatives type isocombretastatin A-4 and isoerianin analogues: Synthesis, cytotoxicity and antitubulin activity

Published:2012-06 Issue: Volume:52 Page:22-32
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Rasolofonjatovo Evelia,Provot Olivier,Hamze Abdallah,Rodrigo Jordi,Bignon Jérome,Wdzieczak-Bakala Joanna,Desravines Déborah,Dubois Joëlle,Brion Jean-Daniel,Alami Mouad

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference49 articles.

1. Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle

2. Natural, semisynthetic and synthetic microtubule inhibitors for cancer therapy

3. Anticancer Agents from Natural Products;Gueritte,2005

4. Microtubules as a target for anticancer drugs

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research progress on the pharmacological mechanism, in vivo metabolism and structural modification of Erianin;Biomedicine & Pharmacotherapy;2024-04

2. Mo-catalyzed cyclization of N-vinylindoles and skatoles: synthesis of dihydroindolo[1,2-c]-quinazolines and dihydroindolo[3,2-b]-indoles, and evaluation of their anticancer activities;Organic Chemistry Frontiers;2024

3. Synthesis of 1-Aryltetralins via Re₂O₇/HReO₄ Mediated Intramolecular Hydroarylations;The Journal of Organic Chemistry;2023-08-10

4. Stereospecific/stereoselective nickel catalyzed reductive cross-coupling: An efficient tool for the synthesis of biological active targeted molecules;Journal of Saudi Chemical Society;2023-01

5. Demonstrating Tumor Vascular Disrupting Activity of the Small-Molecule Dihydronaphthalene Tubulin-Binding Agent OXi6196 as a Potential Therapeutic for Cancer Treatment;Cancers;2022-08-30